Aurobindo Pharma
Aurobindo Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Aurobindo Pharma
Start SIPAurobindo Pharma Investment Rating
-
Master Rating:
-
Aurobindo Pharma has an operating revenue of Rs. 24,855.38 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 29% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 44 which is a POOR score indicating inconsistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 104 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 3,484 | 3,418 | 2,970 | 2,735 | 2,878 |
| Operating Expenses Qtr Cr | 2,856 | 2,959 | 2,730 | 2,545 | 2,380 |
| Operating Profit Qtr Cr | 692 | 473 | 296 | 242 | 507 |
| Depreciation Qtr Cr | 115 | 109 | 109 | 103 | 101 |
| Interest Qtr Cr | 49 | 39 | 19 | 8 | 5 |
| Tax Qtr Cr | 171 | 106 | 59 | 48 | -63 |
| Net Profit Qtr Cr | 645 | 299 | 165 | 122 | 802 |
Aurobindo Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹621.67
- 50 Day
- ₹583.73
- 100 Day
- ₹547.2
- 200 Day
- ₹538.78
- 20 Day
- ₹620.19
- 50 Day
- ₹580.51
- 100 Day
- ₹514.69
- 200 Day
- ₹510.42
Aurobindo Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹664.42 |
| Second Resistance | ₹670.14 |
| Third Resistance | ₹679.27 |
| RSI | 71.16 |
| MFI | 69.99 |
| MACD Single Line | 15.56 |
| MACD | 18.75 |
| Support | |
|---|---|
| First Resistance | ₹649.57 |
| Second Resistance | ₹640.44 |
| Third Resistance | ₹634.72 |
Aurobindo Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,295,924 | 38,139,043 | 29.43 |
| Week | 4,204,514 | 93,382,260 | 22.21 |
| 1 Month | 2,039,402 | 58,571,637 | 28.72 |
| 6 Month | 1,821,143 | 64,850,893 | 35.61 |
Aurobindo Pharma Result Highlights
Aurobindo Pharma Synopsis
NSE-Medical-Generic Drugs
Aurobindo Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 12792.28 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2023. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.| Market Cap | 38,818 |
| Sales | 12,792 |
| Shares in Float | 28.12 |
| No of funds | 625 |
| Yield | 1.13 |
| Book Value | 2.17 |
| U/D Vol ratio | 2.5 |
| LTDebt / Equity | |
| Alpha | 0.07 |
| Beta | 0.91 |
Aurobindo Pharma
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 51.83% | 51.83% | 51.83% | 51.83% |
| Mutual Funds | 7.64% | 7.5% | 8.96% | 9.82% |
| Insurance Companies | 7.2% | 7.15% | 7.26% | 5.76% |
| Foreign Portfolio Investors | 23.03% | 22.31% | 21.41% | 20.71% |
| Financial Institutions/ Banks | 0.01% | |||
| Individual Investors | 8.54% | 9.42% | 8.64% | 8.8% |
| Others | 1.76% | 1.79% | 1.89% | 3.08% |
Aurobindo Pharma Management
| Name | Designation |
|---|---|
| Mr. K Ragunathan | Non Executive Chairman |
| Mr. K Nithyananda Reddy | Vice Chairman & Mng.Director |
| Mr. P Sarath Chandra Reddy | Whole Time Director |
| Dr. M Sivakumaran | Whole Time Director |
| Mr. M Madan Mohan Reddy | Whole Time Director |
| Mr. P V Ramprasad Reddy | Non Executive Director |
| Mrs. Savita Mahajan | Ind. Non-Executive Director |
| Mr. Girish P Vanvari | Ind. Non-Executive Director |
| Dr.(Mrs.) Avnit Bimal Singh | Ind. Non-Executive Director |
Aurobindo Pharma Forecast
Price Estimates
Aurobindo Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-27 | Audited Results | |
| 2023-02-09 | Quarterly Results & Interim Dividend | |
| 2022-11-12 | Quarterly Results | |
| 2022-08-11 | Quarterly Results | |
| 2022-05-30 | Audited Results & 4th Interim Dividend |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-17 | INTERIM | Rs.3.00 per share(300%)Interim Dividend |
| 2022-06-07 | INTERIM | Rs.4.50 per share (450%) Fourth Interim Dividend |
| 2022-02-21 | INTERIM | Rs.1.50 per share(150%)Third Interim Dividend |
| 2021-11-18 | INTERIM | Rs.1.50 per share (150%) Second Interim Dividend |
| 2021-08-30 | INTERIM | Rs.1.50 per share(150%)Interim Dividend |
Aurobindo Pharma FAQs
What is Share Price of Aurobindo Pharma ?
Aurobindo Pharma share price is ₹662 As on 05 June, 2023 | 02:03
What is the Market Cap of Aurobindo Pharma ?
The Market Cap of Aurobindo Pharma is ₹38818.4 Cr As on 05 June, 2023 | 02:03
What is the P/E ratio of Aurobindo Pharma ?
The P/E ratio of Aurobindo Pharma is 20.1 As on 05 June, 2023 | 02:03
What is the PB ratio of Aurobindo Pharma ?
The PB ratio of Aurobindo Pharma is 1.4 As on 05 June, 2023 | 02:03
Is it a good time to invest in Aurobindo Pharma?
Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.
How many times have Aurobindo Pharma given dividends since 2000?
Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.
What is the stock price CAGR of Aurobindo Pharma?
The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.
What is the ROE of Aurobindo Pharma?
Aurobindo Pharma has an ROE of 24% which is exceptional.
What is Aurobindo Pharma’s debt to equity?
Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.